RxDoctor Payments Data

Minal Patel, PA

Medical · Wyomissing, PANPI 1871681056

Payments from drug & device makers

$8,721in general payments, 2019–2025

Across 501 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$654
  • Takeda Pharmaceuticals U.S.A., Inc.$646
  • Regeneron Healthcare Solutions, Inc.$533
  • Sanofi$524
  • Madrigal Pharmaceuticals$420
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$8,695100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,721 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$42,158
Medicare patients
305
Services billed
475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide140$97,593
Mesalamine20$19,634
TrulancePlecanatide19$10,280
Omeprazole446$6,170
Lubiprostone35$5,546
Pantoprazole Sodium341$4,493
Colestipol Hcl32$3,570
Dexlansoprazole DrDexlansoprazole11$3,433
Esomeprazole Magnesium37$1,466
Lansoprazole54$1,449
Dicyclomine Hcl69$1,303
Ondansetron OdtOndansetron12$1,205
Balsalazide Disodium15$817
Famotidine123$798
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate13$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,686$97,593140 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$362$10,28019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →